EquityBulls

Latest News

Reliance Power Ltd clarifies on provisional attachment of assets by ED
Fino becomes India's first Payments Bank to receive 'In-principle' approval from RBI for conversion into a Small Finance Bank
Fire at Aditya Vision Ltd's warehouse
Shriram Pistons & Rings Ltd announces Definitive Agreement to acquire 100% stake in Antolin Group's Indian Operations
Supreme Petrochem Ltd announces temporary closure of plant at Manali, Chennai

Keywords Selected: USFDA

Stock Report

Ipca Laboratories Ltd receives 3 observations from USFDA for API facility at Tarapur
Lupin receives tentative approval from U.S. FDA for Siponimod Tablets
Granules India's Packaging Facility in US Completes FDA inspection with Zero Observations
US FDA Accepts Wockhardt's New Drug Application for Breakthrough Antibiotic Zaynich
Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg
Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility
SMS Pharmaceutical's associate company, VKT Pharma, receives US FDA approval for its reformulated Ranitidine
Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg
Shilpa Medicare Ltd receives 8 observations from USFDA for Unit 4 at Jadcherla
Lupin Ltd receives 7 observations from USFDA for Goa manufacturing facility
NATCO Pharma Ltd receives 7 Observations from USFDA for API unit at Manali, Chennai
Marksans Pharma Inc. receives USFDA approval for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
Solara announces successful closure of US FDA inspection of its Mangalore Facility with continued state of compliance on cGMP
Biocon Pharma Ltd receives approval from USFDA for its ANDA
Lupin announces closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations
Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP, 30 mg, 60 mg, 90 mg, and 120 mg
Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial
Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities Ltd
USFDA inspects Unit 1 of Divi's Laboratories Limited
Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad
Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg
Alembic Pharmaceuticals Ltd announces USFDA Final Approval Dexlansoprazole Delayed Release Capsules, 30 mg and 60 mg